The predicted activities of all modified compounds are presented in Table S4. Similarly to the tested compounds, the modified compounds were categorized according to their predicted activity (Prachayasittikul et al., 2014). The majority of the modified compounds were predicted as moderately active aromatase inhibitors. Some of the modified compounds (Table S4) exhibited more potent activity than the reference drug ketoconazole but less than letrozole (i.e., 1a, 1c, 2f, 3a, 4a, 4b, 4d, 4e, 4f, 5d, 6c, 7b, 7c, 8a, 8b and 8c).